摘要
目的研究原发性肝癌患者实施介入化疗栓塞治疗的效果及对细胞免疫功能的影响。方法选取我院2015年10月~2016年10月接受介入化疗栓塞治疗的原发性肝癌患者50例纳入实验组,另选取同期50名于我院行体检的健康志愿者纳入参照组,对实验组患者治疗前后及志愿者均行细胞免疫功能检验,对比其免疫功能指标,同时比较不同肝功能的原发性肝癌患者介入化疗栓塞治疗期间不良反应发生情况,并总结肝癌患者应用介入化疗栓塞治疗3年生存率。结果实验组治疗前后CD3^+及治疗后与参照组CD4+/CD8+水平无显著差异(P>0.05),实验组治疗前后与参照组CD3^+、CD4^+、CD8^+、CD4^+/CD8^+差异明显(P<0.05)。原发性肝癌患者发热发生比例未见显著差异(P>0.05),Child-Pugh分数>6分患者胃肠反应、肝功能损害、骨髓抑制等不良反应发生率明显高于Child-Pugh≤6分患者,差异有显著性(P<0.05)。2年总生存率为24.00%。结论与健康群体相比,原发性肝癌患者细胞免疫功能有所下降,应用介入化疗栓塞治疗能够提升其细胞免疫功能,临床治疗效果较好,且不良反应发生率较低,应予以临床推广。
Objective To study the effect of interventional chemotherapy and embolization in patients with primary liver cancer and its influence on cellular immune function index.Methods 50 patients with primary liver cancer who underwent interventional chemotherapy and embolization from October 2015 to October 2016 were enrolled in the experimental group.50 healthy volunteers who underwent physical examination in our hospital were included in the reference group.The experimental group before and after treatment and volunteers underwent cellular immunological function tests.Their immune function indexes were compared.And the adverse reactions during the interventional chemotherapy and embolization treatment of primary liver cancer patients with different liver functions were compared.And the three-year survival rate of patients with liver cancer treated with interventional chemotherapy and embolization was summarized.Results There was no significant difference in CD3^+and CD41^+/CD8^+levels in the experimental group before and after treatment(P>0.05).There were significant differences in CD3^+,CD4^+,CD8^+,CD41^+/CD8^+between the experimental group and the reference group before and after treatment(P<0.05).There was no significant difference in the incidence of fever in patients with primary liver cancer(P>0.05).The incidence of adverse reactions such as gastrointestinal reaction,liver function damage and myelosuppression in Child-Pugh scores>6 was significantly higher than that in the patient with Child-Pugh scores≤6,and the difference was significant(P<0.05).The 2-year overall survival rate was 24.00%.Conclusion Compared with that of healthy people,the cellular immune function of patients with primary liver cancer has decreased.The application of interventional chemotherapy and embolization can improve their cellular immune function.The clinical treatment effect is better and the incidence of adverse reactions is lower.It should be promoted in clinical.
作者
饶春晖
陆淼炯
RAO Chunhui;LU Miaojiong(Department of Anorectal Surgery,Hangzhou Hospital of Traditional Chinese Medicine,Hangzhou 310007,China)
出处
《中国现代医生》
2019年第13期22-25,共4页
China Modern Doctor
基金
浙江省中医药科学研究基金项目(2018ZB088)
关键词
介入化疗栓塞
原发性肝癌
细胞免疫功能
不良反应
Interventional chemotherapy and embolization
Primary liver cancer
Cellular immune function
Adverse reactions
